Table 6 Univariate analysis for predictors of time to CNS metastases
Variables | No. of patients (%) | Median time to CNS metastases, mo (95% CI) | Pvalue |
|---|---|---|---|
Age (yrs) | Â | Â | 0.056 |
  <60 | 16 (55.2) | 27.3 (17.5-37.1) |  |
  > = 60 | 13 (44.8) | 22.9 (14.4-29.4) |  |
FIGO stage | Â | Â | 0.021 |
  1,2 | 3 (10.3) | 45.1 (10.5-79.7) |  |
  3,4 | 26 (89.7) | 22.7 (18.7-26.7) |  |
Pathology of primary cancer | Â | 0.595 | |
  Serous | 16 (55.2) | 25.7 (16.5-34.9) |  |
  Non-serous | 13 (44.8) | 22.7 (20.8-24.6) |  |
Histological grade | Â | 0.354 | |
  1,2 | 5 (21.7) | 27.7 (18.7-36.7) |  |
  3, | 18 (78.3) | 21.9 (17.1-26.7) |  |
Extent of surgical resection | Â | <0.0001* | |
  TAH + BSO | 23 (79.3) | 27.7 (23.0-32.4) |  |
  Limited | 5 (17.2) | 16.3 (15.4-17.2) |  |
  Biopsy | 1 (3.4) | 6.2 |  |
Lymph node metastasis | Â | 0.026 | |
  No | 11 (37.9) | 31.7 (24.4-39.0) |  |
  Yes | 18 (62.1) | 22.0 (21.6-22.4) |  |
Ascites at the time of primary surgery | 0.153 | ||
  No | 10 (34.5) | 29.0 (22.8-35.2) |  |
  Yes | 19 (65.5) | 22.1 (21.2-23.0) |  |
Adjuvant therapy |  |  | 0.683†|
  Chemotherapy | 25 (86.2) | 25.3 (20.4-30.2) |  |
  Chemotherapy + Radiotherapy | 3 (10.3) | 21.9 (14.9-28.9) |  |
  None | 1 (3.4) | 23.5 |  |
Platinum sensitivity | Â | <0.0001 | |
  Sensitive | 16 (57.1) | 29.0 (16.8-41.2) |  |
  Resistant | 12 (42.9) | 16.3 (13.6-19.0) |  |
CD133 expression | Â | Â | 0.033 |
  Negative | 15 (51.7) | 29.0 (20.9-37.1) |  |
  Positive | 14 (48.3) | 19.8 (11.7-27.9) |  |